You are here:

tenofovir disoproxil (Viread)

Advice

following a full submission

tenofovir disoproxil (as fumarate) (Viread®) is accepted for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis B in adults with decompensated liver disease.

Interim results of an ongoing phase II study assessing the safety of tenofovir disoproxil in the treatment of chronic hepatitis B in patients with decompensated liver disease demonstrated that tenofovir was as well tolerated as another nucleoside/nucleotide analogue.  Comparative efficacy was not tested in this study, but has been extrapolated from a mixed treatment comparison in treatment-naïve patients with compensated liver disease and hepatitis B e-antigen positive infection.

Drug Details

Drug Name: tenofovir disoproxil (Viread)
SMC Drug ID: 720/11
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of chronic hepatitis B in adults with decompensated liver disease
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 September 2011

Back